Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance for Industry

flok Health, a patient-led organization for individuals with inherited disorders of protein metabolism, supports the FDA's Plausible Mechanism Framework for individualized therapies. They urge the FDA to incorporate structured real-world data as a foundational evidence stream and to leverage shared mechanisms and platform approaches to improve access for patients with ultra-rare variants.

The Sanfilippo Initiative, representing the Sanfilippo patient community, supports the Plausible Mechanism Framework as a necessary approach for developing therapies for ultra-rare diseases. They urge the FDA to ensure the framework applies to all therapeutic modalities (such as enzyme replacement and small molecules) and to provide flexibility regarding biomarkers and natural history data in small patient populations.

The Critical Path Institute (C-Path), a nonprofit organization, supports the FDA's draft guidance on the Plausible Mechanism Framework for developing individualized therapies. They recommend providing greater clarity on statutory alignment, evidentiary expectations for mechanistic data, the role of biomarkers, and the integration of natural history data and quantitative modeling to ensure consistent regulatory decision-making.

The National Center for Health Research (NCHR), a nonprofit think tank, opposes the proposed guidance because it allows for the approval of individualized therapies based on insufficient evidentiary standards, such as small nonrandomized studies and surrogate endpoints. They argue that the framework lacks clear criteria for patient population size, fails to ensure robust post-market evidence, and risks creating "financial toxicity" by approving expensive, unproven treatments.

The Alliance for mRNA Medicines (AMM) supports the FDA's Plausible Mechanism Framework but urges the agency to provide greater clarity on its scope, manufacturing requirements, and clinical data expectations for very rare diseases. They specifically advocate for a more flexible, platform-based regulatory approach that accounts for the unique lifecycle and logistical challenges of individualized therapies.

The Personalized Medicine Coalition (PMC), a multi-stakeholder group, supports the FDA's draft guidance on the Plausible Mechanism Framework for developing individualized therapies for rare genetic conditions. They applaud the effort to create a pathway for personalized medicine but urge the FDA to provide further clarification on safety/efficacy data extrapolation, manufacturing standards, and the scope of permissible personalization.

The Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women’s Hospital and Harvard Medical School supports the draft guidance but recommends specific refinements. They argue for limiting the framework to ultra-rare diseases, enhancing post-marketing safety monitoring, prioritizing the accelerated approval pathway, and increasing transparency regarding surrogate endpoints and platform-based approvals.

The Biotechnology Innovation Organization (BIO) supports the FDA's proposal to create a Plausible Mechanism Framework for individualized therapies, viewing it as a necessary evolution in regulatory science. They request additional clarity on operational details, including broader scope for modalities, clearer definitions, expanded CMC flexibilities, and better integration with existing regulatory pathways.

ALS United, a nationwide partnership of nonprofit organizations, supports the FDA's draft guidance on the Plausible Mechanism Framework for individualized therapies. They argue that the framework should specifically include mutation-defined subsets of ALS while maintaining rigorous standards for biomarker validation, confirmatory studies, and safety oversight.

Friends of Cancer Research supports the draft guidance as an important step toward clarifying the plausible mechanism framework for individualized therapies. They request additional clarity on CMC expectations, definitions for "well-characterized" natural history data, assay standardization for platform trials, and strategies for data leveraging across product variants.